MASSACHUSETTS GENERAL HOSPITAL

The STORM-PE randomized controlled trial demonstrated that computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation significantly reduced right heart strain compared to anticoagulation alone in intermediate-high risk pulmonary embolism patients.

Kamada has enrolled the first patient in the SHIELD trial, an investigator-initiated study evaluating CYTOGAM to prevent late cytomegalovirus infection in high-risk kidney transplant recipients.

COVID-19 vaccination within 6 months before first infection reduced long COVID risk by 36% in adolescents aged 12-17 years, according to analysis of RECOVER-Pediatrics trial data.

Tonix Pharmaceuticals has dosed the first patient in the FOCUS study, evaluating intranasal potentiated oxytocin products TNX-1900 and TNX-2900 for arginine-vasopressin deficiency (AVP-D), a rare endocrine disorder formerly known as central diabetes insipidus.

Doctors plan to request FDA approval this winter for a clinical trial testing CRISPR base editing in seven different urea cycle disorders, following the successful treatment of baby KJ with CPS1 deficiency.

Sonoma Biotherapeutics announced positive interim results from its Phase 1 REGULATE-RA trial of SBT-77-7101, showing a favorable safety profile with no dose-limiting toxicities or cytokine release syndrome in refractory rheumatoid arthritis patients.

Tonix Pharmaceuticals presented Phase 1 safety and biomarker data for TNX-1500, a third-generation Fc-modified anti-CD40L monoclonal antibody designed to prevent organ transplant rejection.

Mass General Brigham researchers demonstrated that a wearable heart rate variability biofeedback device significantly reduced substance cravings and use in early recovery patients.

SELLAS Life Sciences will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders discussing acute myeloid leukemia treatment advances and unmet medical needs.

Researchers at Massachusetts General Hospital have developed a biodegradable wafer implant called CANDI that reprograms immune cells to fight glioblastoma recurrence after surgical removal.